Glizorem

Glizorem is a prescription medication that contains the active ingredient gliclazide, a sulfonylurea class antidiabetic agent. It is administered orally and is marketed in the European Union. Gliclazide works by stimulating insulin release from pancreatic beta cells, helping to lower blood glucose levels in people with type 2 diabetes mellitus. Glizorem is supplied as a tablet formulation, though specific strengths may vary by market generally.

Glizorem (gliclazide) is indicated for the management of type 2 diabetes mellitus as part of a comprehensive treatment plan.

- Used as monotherapy when diet and exercise alone do not achieve glycemic control. - Combined with other oral antidiabetic agents such as metformin to improve blood glucose lowering. - Prescribed for patients with stable renal function who require a sulfonylurea. - Adjusted in elderly patients to reduce risk of hypoglycemia. - May be considered when a long‑acting sulfonylurea is preferred.

The safety profile of Glizorem reflects the typical effects observed with sulfonylurea medications, ranging from mild, frequently reported events to rare but serious reactions.

Common: - Mild hypoglycemia, especially if meals are missed or delayed. - Gastrointestinal discomfort such as nausea, abdominal pain, or dyspepsia. - Headache or dizziness. - Weight gain due to increased insulin activity. - Transient visual disturbances such as blurred vision. - Mild fatigue or weakness.

Serious: - Severe hypoglycemia leading to loss of consciousness or seizures. - Allergic reactions including skin rash, pruritus, or angio‑edema. - Hematologic abnormalities such as leukopenia or thrombocytopenia. - Hepatic dysfunction presenting as jaundice or elevated liver enzymes. - Pancreatitis presenting with upper abdominal pain. - Cardiovascular events such as arrhythmia.

When prescribing Glizorem, clinicians consider several precautions to minimize risks and ensure safe use in diverse patient populations.

- Assess renal and hepatic function before initiating therapy and periodically thereafter. - Use lower starting doses in elderly patients or those with reduced kidney function. - Monitor blood glucose closely to avoid hypoglycemia, especially when dietary patterns change. - Counsel patients on recognizing signs of low blood sugar and the importance of regular meals. - Avoid use during pregnancy or breastfeeding unless benefits clearly outweigh potential risks. - Review concomitant medications that may potentiate hypoglycemia.

Glizorem may interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or insulin that can cause severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise gliclazide plasma levels. - MAO‑B inhibitors, which have been reported to enhance sulfonylurea hypoglycemic action. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may displace gliclazide from plasma proteins, increasing free drug.

Use with caution: - Beta‑blockers, as they may mask hypoglycemia symptoms. - Thiazide diuretics, which can affect blood glucose control. - Corticosteroids, because they may increase glucose levels and require dose adjustments. - Alcohol consumption, which can potentiate hypoglycemia and should be limited.